BridgeBio's Attruby Challenges Pfizer's Tafamidis in ATTR-CM with Late-Stage Data Hinting at Superior Survival and Reduced Hospitalizations
BridgeBio's Phase 3 ATTRibute-CM trial showed Attruby (acoramidis) significantly increased serum transthyretin levels and reduced variability, linked to 20% lower all-cause mortality risk.
Indirect comparison via matching-adjusted analysis revealed Attruby reduced cardiovascular hospitalizations by 34% and all-cause mortality risk by 28% versus Pfizer's tafamidis (Vyndamax/Vyndaqel), though not head-to-head.
Attruby approved in November 2024, generated $362.4M revenue last year; tafamidis hit $1.7B.
Long-term data from ATTRibute-CM OLE to be presented at ACC 2026 (March 28-30).
Pfizer settled patent disputes, extending Vyndamax US exclusivity to 2031.